D. C. Guven Et Al. , "Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, pp.203-204, 2022
Guven, D. C. Et Al. 2022. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1 , 203-204.
Guven, D. C., Taban, H., & Dizdar, O., (2022). Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, 203-204.
Guven, D., HAKAN TABAN, And ÖMER DİZDAR. "Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, 203-204, 2022
Guven, D. C. Et Al. "Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, pp.203-204, 2022
Guven, D. C. Taban, H. And Dizdar, O. (2022) . "Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.1, pp.203-204.
@article{article, author={D. C. Guven Et Al. }, title={Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2022, pages={203-204} }